<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234169</url>
  </required_header>
  <id_info>
    <org_study_id>05/09</org_study_id>
    <nct_id>NCT00234169</nct_id>
  </id_info>
  <brief_title>A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone</brief_title>
  <official_title>A Phase I/II Study of Peripheral Blood Progenitor Cells Mobilisation With VTP195183 Plus G-CSF Compared to Mobilisation With G-CSF Alone in Patients With Multiple Myeloma and Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hematopoietic stem cells (HSC) are used to support the administration of high dose&#xD;
      chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5&#xD;
      million HSC per kilogram are required. HSC are collected from the bone marrow by using drugs&#xD;
      such as G-CSF (filgrastim) which 'mobilize' them from the bone marrow into the bloodstream.&#xD;
      HSC are collected from the bloodstream using an apheresis machine. Between 5 and 60% of&#xD;
      patients fail to mobilize the minimum HSC dose required for safe transplantation, and this&#xD;
      trial is investigating a way to enhance mobilization to overcome this problem. This trial&#xD;
      aims to determine if a new vitamin A derivative is capable of enhancing HSC mobilization when&#xD;
      used in conjunction with G-CSF. Patients will undergo two mobilization procedures. They will&#xD;
      be given G-CSF alone, or a combination of the study drug plus G-CSF, and their stem cells&#xD;
      will be collected. A comparison group of patients will be given G-CSF alone for both&#xD;
      mobilizations. Stem cells collected from patients in this trial will be frozen and stored&#xD;
      until they are required for transplantation into that patient. At that time, patients will be&#xD;
      monitored for how well they recover from their high dose chemotherapy and HSC&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PB CD34+ kinetics using VTP195183 plus G-CSF</measure>
    <time_frame>up to 28 days post study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The toxicity of VTP195183 pretreatment when used with G-CSF</measure>
    <time_frame>within 28 days of study drug administration</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VTP195183</intervention_name>
    <description>VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.&#xD;
Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70&#xD;
&#xD;
          2. Histologically proven multiple myeloma or lymphoma&#xD;
&#xD;
          3. Intent of treating physician to proceed to high dose therapy and autologous&#xD;
             transplantation&#xD;
&#xD;
          4. Not currently receiving thalidomide (within 1 week of commencing VTP195813 or G-CSF),&#xD;
             cytotoxic agents or high dose prednisolone or Dexamethasone (at doses greater than 15&#xD;
             mg prednisolone or equivalent per day)&#xD;
&#xD;
          5. Multiple myeloma patients must be taking regular bisphosphonate therapy&#xD;
&#xD;
          6. Absolute neutrophil count between 1.5 and 10 x 109/L&#xD;
&#xD;
          7. ECOG performance status ? 2&#xD;
&#xD;
          8. Life expectancy of at least 2 months&#xD;
&#xD;
          9. Written informed consent signed by patient or legally authorized representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection or a fever &gt; 38.2 degrees C (fever due to B symptoms in lymphoma&#xD;
             patients will not exclude a patient)&#xD;
&#xD;
          2. Use within the previous 30 days of other vitamin A preparations within the last 30&#xD;
             days (including oral vitamin supplements, oral retinoids for acne or other skin&#xD;
             disorders, bexarotene, or topical vitamin A preparations)&#xD;
&#xD;
          3. Pregnancy or breast feeding. Women of child-bearing potential, admitted to the trial&#xD;
             must take adequate measures to prevent conception (at least two different forms of&#xD;
             contraception during the study and for at least one month after completion of study&#xD;
             drugs) and are to undergo a pregnancy test&#xD;
&#xD;
          4. Significant non-malignant disease including HIV infection, uncontrolled hypertension&#xD;
             (diastolic blood pressures &gt; 115 mmHg), unstable angina&#xD;
&#xD;
          5. Known allergy to E.coli-derived products&#xD;
&#xD;
          6. Current treatment with tetracycline antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Herbert, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peter MacCallum Cancer centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peter MacCallum Cancer Centre, Australia</investigator_affiliation>
    <investigator_full_name>Kirsten Herbert</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

